Bioactivity:

Olutasidenib is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Olutasidenib is a highly effective, brain penetrant, and selective inhibitor of the mutant Isocitrate dehydrogenase 1 (IDH1) (IC50: 21.2 nM

CAS nr:

1887014-12-1

Purity:

98%

Molecular Weight:

354,79

SMILES:

C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O

Formula:

C18H15ClN4O2

Pathway:

Metabolism,Metabolism

Target:

Isocitrate Dehydrogenase (IDH),Dehydrogenase